ArticleCancer causes & control : CCC2014
Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study.
Article in Cancer causes & control : CCC, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Appetite-regulating hormones-leptin, adiponectin and ghrelin-and the development of prostate cancer: a systematic review and exploratory meta-analysis.Prostate cancer and prostatic diseases · 2020Pooled it
- Serum C-peptide concentration and prostate cancer: A meta-analysis of observational studies.Medicine · 2018Pooled it
- Pooled it
- Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.Carcinogenesis · 2018Trial
- Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.BJU international · 2015Trial
- Role of Metabolism and Metabolic Pathways in Prostate Cancer.Metabolites · 2023Review
- Could Reducing Body Fatness Reduce the Risk of Aggressive Prostate Cancer via the Insulin Signalling Pathway? A Systematic Review of the Mechanistic Pathway.Metabolites · 2021Review
- Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs.Cancer cell international · 2021Review
- Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer.European urology · 2021Article
- Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer.Disease markers · 2018Article
- Association between insulin-like growth factor-binding protein-3 polymorphism-202 A/C and the risk of prostate cancer: a meta-analysis.OncoTargets and therapy · 2016Review
- Diabetes and mortality in patients with prostate cancer: a meta-analysis.SpringerPlus · 2016Review
- Plasma Leptin Levels and Risk of Incident Cancer: Results from the Dallas Heart Study.PloS one · 2016Article
- Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.Physiological reviews · 2015Review
- Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.International journal of cancer · 2015Article
- Association of interleukin-6 (-174 G/C) polymorphism with the prostate cancer risk: A meta-analysis.Biomedical reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeHyperinsulinemia is hypothesized to influence prostate cancer risk. Thus, we evaluated the association of circulating C-peptide, which is a marker of insulin secretion, and leptin, which is secreted in response to insulin and influences insulin sensitivity, with prostate cancer risk.
methodsWe identified prostate cancer cases (n = 1,314) diagnosed a mean of 5.4 years after blood draw and matched controls (n = 1,314) in the Health Professionals Follow-up Study. Plasma C-peptide and leptin concentrations were measured by ELISA. Odds ratios (ORs) and 95 % confidence intervals (CI) were estimated taking into account the matching factors age and history of a PSA test before blood draw and further adjusting for body mass index, diabetes, and other factors.
resultsNeither C-peptide (quartile [Q]4 vs. Q1: OR 1.05, 95 % CI 0.82-1.34, p-trend = 0.95) nor leptin (Q4 vs. Q1: OR 0.85, 95 % CI 0.65-1.12, p-trend = 0.14) was associated with prostate cancer risk. Further, neither was associated with risk of advanced or lethal disease (n = 156 cases; C-peptide: Q4 vs. Q1, OR 1.18, 95 % CI 0.69-2.03, p-trend = 0.78; leptin: Q4 vs. Q1, OR 0.74, 95 % CI 0.41-1.36, p-trend = 0.34).
conclusionsIn this large prospective study, circulating C-peptide and leptin concentrations were not clearly associated with risk of prostate cancer overall or aggressive disease. Well into the PSA era, our findings do not appear to be supportive of the hypothesis that hyperinsulinemia influences risk of total or aggressive prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.